Analysis of TP53 mutations in human malignant gliomas
β Scribed by Norman, Sylvia; Scheck, Adrienne; Braman, Jeff
- Book ID
- 109830480
- Publisher
- Nature Publishing Group
- Year
- 2001
- Tongue
- English
- Weight
- 83 KB
- Volume
- 27
- Category
- Article
- ISSN
- 1061-4036
- DOI
- 10.1038/87226
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The p53 gene (TP53) is mutated in numerous human cancers. We have used it as a molecular target to characterize the induction of mutations in human skin cancers. About 50% of all skin cancers in normal individuals exhibit p53 mutations. This frequency rises to 90% in skin cancers of patients with th
Neurofibromatosis type I (NFI) is a common autosomal dominant disorder with an increased risk for developing benign and malignant tumors. The NFI gene has been cloned and maps to 17q I I .2, and the gene product acts as a tumor suppressor gene. Here we analyzed the role of mutations in TP53 in four
Analysis of the literature reporting p53 mutations shows that 8% of report display typographical mistakes with a notable increase in recent years. These errors are sometimes isolated, but in some cases, they concern several or even all mutations described in a single article. Furthermore, some works
Loss of p53 function is involved in tumorigenesis of various human cancers, but the relation between mutation of the p53 tumor-suppressor gene and the chemo-and radiosensitivity of tumors remains unclear. Mutated p53 gene in malignant glioma is often associated with progression and recurrence of rna
A detailed analysis of p53 (TP53) mutations involving the 42 CpG dinucleotides was performed to gain greater insight into the mutational mechanism leading to specific selection of these mutations. Although the majority of these CpG dinucleotides have been found to be mutated in cancer cells, the het